The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Why assessing t(11;14) can be the first step towards personalized therapy in MM?
Featured:
Rafael FonsecaDuring the Lymphoma, Leukemia & Myeloma 2021 Virtual Congress, the MM hub was pleased to speak to Rafael Fonseca, Mayo Clinic, Phoenix, US. We asked, Why assessing t(11;14) can be the first step towards personalized therapy in MM?
Why assessing t(11;14) can be the first step towards personalized therapy in MM?
In this video, Fonseca discusses the translocation (11;14) and its impact in personalized therapy for patients with multiple myeloma.